Alignment Healthcare (ALHC) is under scrutiny after a whistleblower accused the company of inflating financial results by classifying operating expenses as capital expenditures. This has triggered multiple law firm investigations and a sharp stock reaction.
See our latest analysis for Alignment Healthcare.
At a share price of $13.46, Alignment Healthcare has seen its 30 day share price return fall 36.51% and its year to date share price return decline 33.43%. However, the 3 year total shareholder return is 119.22%, which points to longer term gains despite recent pressure following the whistleblower allegations and the July 8 drop.
If the recent volatility around Alignment Healthcare has you reassessing your watchlist, this can be a good moment to look across the sector and check out 44 healthcare AI stocks
After a sharp drop on the whistleblower claims and fresh earnings numbers from Alignment Healthcare, the key issue now is whether the recent sell off leaves more downside risk or a valuation that still rewards buyers.
At a last close of $13.46 against a narrative fair value of $24.92, Alignment Healthcare is framed as deeply undervalued, with that gap resting on specific revenue and margin expectations discounted at 7.11%.
Alignment's robust, technology-enabled care model and investments in administrative automation, workflow standardization, and digital health platforms position the company to significantly lower SG&A...
Chinese authorities have ordered major e-commerce platforms to remove 35 online stores operating under the name "Hong Kong Pharmacy" as part of a crackdown on fraudulent medical marketing, the Nati...